PSA: The 'Ozempic Dupes' Are Coming, and They Might Work Even Better
Kennedy Jr., who was tapped to lead the Department of Health and Human Services for the Trump administration, recently ...
Altimmune to test obesity drug for alcohol use disorder and related health conditions
Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat alcohol use disorder and alcohol-associated liver disease. WHY IT'S IMPORTANT ...
Hims & Hers, Zealand, and Roche fall: Why weight loss drug stocks are down today
Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 ...
The FDA Cracking Down on Compounded Weight Loss Drugs – Here’s What It Means for Telehealth Companies and Consumers
After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...
Trump’s $1.4 Trillion Tariff Threat Spurs Companies to Seek Cover
Supply Lines is a daily newsletter that tracks global trade. Sign up here.Most Read from BloombergTrump DEI Purge Hits ...
Oz’s ties to insurers may loom over his CMS confirmation hearing
Mehmet Oz will likely face questions during his confirmation hearing about his past support of expanding the Medicare ...
Access to Compounded GLP-1s Is Drying Up. Here’s What to Know About the Copycat Weight-Loss Drugs.
This story mentions weight, weight loss, and/or GLP-1 drugs. In the last few years, GLP-1s, prescription weight-loss ...
Becker's Hospital Review15h
10 drugs poised to be best-sellers in 2026
The top 10 projected best-selling medications in 2026, including GLP-1 drugs and AbbVie's Skyrizi, have expected global sales reaching up to $31 billiion.
JD Supra16h
GLP-1 Receptor Agonists and Patent Strategy: Securing Patent Protection for New Use of Old Drugs
GLP-1 receptor agonists (GLP-1RAs) were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management ...